SUPN

SEC source: 0001628280-24-047145 · wk-form4_1731445977.xml · nonDerivative · entry 2

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,315

F1 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.01 to $36.57. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001628280-24-047145 · wk-form4_1731445977.xml · nonDerivative · entry 1

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,102

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-047142 · wk-form4_1731445884.xml · derivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 125,000 shares

Expires 2025-03-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 3, 2016.

SEC source: 0001628280-24-047142 · wk-form4_1731445884.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 926,172

F1 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.87 to $36.66. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001628280-24-047142 · wk-form4_1731445884.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,051,172

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-046668 · wk-form4_1731100428.xml · derivative · entry 3

Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2025-03-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested in four equal installments beginning on March 3, 2016.

SEC source: 0001628280-24-046668 · wk-form4_1731100428.xml · nonDerivative · entry 2

Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,200

F2 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.73 to $37.27. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001628280-24-046668 · wk-form4_1731100428.xml · nonDerivative · entry 1

Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes an aggregate of 421 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

SEC source: 0001628280-24-046666 · wk-form4_1731100311.xml · derivative · entry 3

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,787

Underlying: Common Stock · 14,213 shares

Expires 2025-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-046666 · wk-form4_1731100311.xml · nonDerivative · entry 2

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,315

F1 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.50 to $36.89. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001628280-24-046666 · wk-form4_1731100311.xml · nonDerivative · entry 1

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,528

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-046663 · wk-form4_1731100124.xml · derivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2025-03-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 3, 2016.

SEC source: 0001628280-24-046663 · wk-form4_1731100124.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 926,172

F1 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.27 to $37.24. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001628280-24-046663 · wk-form4_1731100124.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,051,172

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-040598 · wk-form4_1726603841.xml · derivative · entry 4

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 10,000 shares

Expires 2025-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-040598 · wk-form4_1726603841.xml · nonDerivative · entry 3

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,315

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.12 to $31.50. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001628280-24-040598 · wk-form4_1726603841.xml · nonDerivative · entry 2

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,315

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-040598 · wk-form4_1726603841.xml · nonDerivative · entry 1

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,315

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.12 to $31.50. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001104659-24-096416 · tm2423065-1_4seq1.xml · derivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023.

F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

SEC source: 0001104659-24-096416 · tm2423065-1_4seq1.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 926,172

F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

SEC source: 0001104659-24-096416 · tm2423065-1_4seq1.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 936,217

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023.

SEC source: 0001104659-24-093484 · tm2422824-1_4seq1.xml · derivative · entry 3

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires not disclosed

F1 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

F1 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

SEC source: 0001104659-24-091319 · tm2422059-1_4seq1.xml · derivative · entry 3

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023.

F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period.

F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period.

SEC source: 0001104659-24-091319 · tm2422059-1_4seq1.xml · nonDerivative · entry 2

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,679

F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

SEC source: 0001104659-24-091319 · tm2422059-1_4seq1.xml · nonDerivative · entry 1

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,251

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023.

SEC source: 0001104659-24-089719 · tm2421712-1_4seq1.xml · derivative · entry 2

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires not disclosed

F2 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period.

F2 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period.

SEC source: 0001104659-24-038482 · tm249377-3_4seq1.xml · derivative · entry 3

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,745

Underlying: Common Stock · 14,491 shares

Expires 2027-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 24, 2018.

SEC source: 0001104659-24-038482 · tm249377-3_4seq1.xml · nonDerivative · entry 2

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,570

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.30 to $35.43. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001104659-24-038482 · tm249377-3_4seq1.xml · nonDerivative · entry 1

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,061

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

SEC source: 0001104659-24-037934 · tm249377-2_4seq1.xml · derivative · entry 3

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,236

Underlying: Common Stock · 400 shares

Expires 2027-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

F2 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 24, 2018.

SEC source: 0001104659-24-037934 · tm249377-2_4seq1.xml · nonDerivative · entry 2

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,570

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

SEC source: 0001104659-24-037934 · tm249377-2_4seq1.xml · nonDerivative · entry 1

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,970

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

SEC source: 0001104659-24-037376 · tm249377-1_4seq1.xml · derivative · entry 3

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,636

Underlying: Common Stock · 12,364 shares

Expires 2027-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 24, 2018.

SEC source: 0001104659-24-037376 · tm249377-1_4seq1.xml · nonDerivative · entry 2

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,570

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.30 to $35.34. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001104659-24-037376 · tm249377-1_4seq1.xml · nonDerivative · entry 1

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

SEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · derivative · entry 6

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,750

Underlying: Common Stock · 26,250 shares

Expires 2030-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

F5 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 21, 2021.

SEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · derivative · entry 5

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 36,116 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on March 1, 2017.

SEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · nonDerivative · entry 4

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,570

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.98 to $33.74. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · nonDerivative · entry 3

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,686

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

SEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · nonDerivative · entry 2

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,570

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.99 to $34.28. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · nonDerivative · entry 1

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,820

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

SEC source: 0001104659-24-034563 · tm248830-1_4seq1.xml · derivative · entry 3

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,116

Underlying: Common Stock · 3,884 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on March 1, 2017.

SEC source: 0001104659-24-034563 · tm248830-1_4seq1.xml · nonDerivative · entry 2

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,570

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.98 to $33.00. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001104659-24-034563 · tm248830-1_4seq1.xml · nonDerivative · entry 1

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,454

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.

SEC source: 0001104659-24-029434 · tm247055-37_4seq1.xml · derivative · entry 3

Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 990 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022.

F3 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022.

F3 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022.

SEC source: 0001104659-24-029434 · tm247055-37_4seq1.xml · nonDerivative · entry 2

Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,779

F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

SEC source: 0001104659-24-029434 · tm247055-37_4seq1.xml · nonDerivative · entry 1

Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,239

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022.

SEC source: 0001104659-24-029432 · tm247055-36_4seq1.xml · derivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023.

F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

SEC source: 0001104659-24-029432 · tm247055-36_4seq1.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 915,217

F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

SEC source: 0001104659-24-029432 · tm247055-36_4seq1.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 932,005

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023.